CVRx Announces Chief Financial Officer Transition
Rhea-AI Summary
CVRx (NASDAQ: CVRX) announced a Chief Financial Officer transition. Jared Oasheim, CFO since 2015, will step down to pursue other opportunities, remain until a successor is appointed, and advise through February 2027. CVRx has started a search for a new CFO.
President and CEO Kevin Hykes highlighted Oasheim’s role in leading the IPO and building the finance organization. CVRx also confirmed that Hykes and Oasheim will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, with a live webcast and archived replay.
Positive
- Orderly CFO transition with advisory support through February 2027
- Long-tenured CFO credited with leading IPO and finance organization build
- Ongoing leadership visibility via Goldman Sachs healthcare conference presentation
Negative
- Experienced CFO stepping down after more than a decade at CVRx
- Uncertainty until a new Chief Financial Officer is identified and appointed
News Market Reaction – CVRX
In the Jun 9 session, CVRX declined 3.70%, reflecting a moderate negative market reaction. Argus tracked a trough of -6.9% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Conference presentation | Neutral | -2.6% | Announced upcoming Goldman Sachs healthcare conference presentation with webcast details. |
| May 20 | Conference presentation | Neutral | +0.2% | Announced William Blair growth conference presentation and webcast access. |
| May 14 | Coverage expansion | Positive | +10.0% | Humana issued Medicare Advantage coverage policy for Barostim therapy effective May 1, 2026. |
| May 11 | Earnings results | Positive | -23.8% | Reported Q1 2026 revenue growth, margin improvement, maintained guidance, and trial progress. |
| May 4 | Trial milestone | Positive | -3.8% | Announced first patient enrollment in large BENEFIT-HF heart failure trial for Barostim. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive or neutral news has often seen mixed to negative next-day price reactions, including sizeable downside on earnings and trial milestones.
Over the past weeks, CVRX has reported multiple corporate and clinical milestones. Earnings on May 11, 2026 showed $14.8M Q1 revenue, 20% year-over-year growth, higher gross margin, and maintained 2026 guidance, yet the stock fell 23.84%. The first BENEFIT-HF patient enrollment on May 4 and a Humana Medicare Advantage coverage policy for Barostim on May 14 represented strategic positives, with only the Humana news driving a strong 9.96% gain. Conference presentation announcements in late May drew minimal or negative reactions.
Key Terms
initial public offering financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Jared Oasheim, the Company’s Chief Financial Officer, will be stepping down from his role to pursue other professional opportunities. To support a seamless transition, Mr. Oasheim will remain with the Company until a successor is appointed and remain available as an advisor through February 2027.
“Jared has been an integral part of CVRx since 2015, and has made a lasting mark on our company over the past decade” said Kevin Hykes, President and Chief Executive Officer of CVRx. “He led CVRx through its initial public offering and built the disciplined finance organization that supports our commercial growth today, all while staying focused on our mission to improve the lives of patients with heart failure. We are grateful for his many contributions and wish him every success.”
“It has been a privilege to help build CVRx alongside such a dedicated team and to play a part in bringing Barostim to more patients,” said Jared Oasheim, Chief Financial Officer of CVRx. “Taking the company public and helping establish its financial foundation has been one of the highlights of my career. I am committed to a seamless transition and look forward to seeing CVRx continue its momentum.”
The Company is initiating a search to identify its next Chief Financial Officer.
Presentation at Goldman Sachs Healthcare Conference
As previously announced, Kevin Hykes and Jared Oasheim will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Wednesday, June 10, 2026 at 8:00 a.m. (ET). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.
Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
